Mining the plasma immunopeptidome for cancer peptides as biomarkers and beyond

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 44, 2010, Pages 18747-18748

  Hickman, Heather D ^a   Yewdell, Jonathan W ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNQ1; TETRAMER; VOLTAGE GATED POTASSIUM CHANNEL;

ALPHA CHAIN; BETA CHAIN; BINDING SITE; CROSS LINKING; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HUMAN; LONG QT SYNDROME; MOLECULAR INTERACTION; NONHUMAN; NOTE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; REPOLARIZATION; STOICHIOMETRY;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; NEOPLASMS; PEPTIDES; PROTEOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78650460280     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1013851107     Document Type: Note

References (20)

1. Yewdell JW, Nicchitta CV (2006) The DRiP hypothesis decennial: Support, controversy, refinement and extension. Trends Immunol 27:368-373.
2. Peaper DR, Cresswell P (2008) Regulation of MHC class I assembly and peptide binding. Annu Rev Cell Dev Biol 24:343-368.
3. Shastri N, Schwab S, Serwold T (2002) Producing nature's gene-chips: The generation of peptides for display by MHC class I molecules. Annu Rev Immunol 20:463-493.
4. Bassani-Sternberg M, et al. (2010) Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc Natl Acad Sci USA 107:18769-18776.
5. Setchell JM, Huchard E (2010) The hidden benefits of sex: Evidence for MHC-associated mate choice in primate societies. Bioessays, 10.1002/bies. 201000066.
6. Bui JD, Schreiber RD (2007) Cancer immunosurveillance, immunoediting and inflammation: Independent or interdependent processes? Curr Opin Immunol 19: 203-208.
7. O'Neill ID (2010) Tasmanian devil facial tumor disease: Insights into reduced tumor surveillance from an unusual malignancy. Int J Cancer 127:1637-1642.
8. Murgia C, Pritchard JK, Kim SY, Fassati A, Weiss RA (2006) Clonal origin and evolution of a transmissible cancer. Cell 126:477-487.
9. Boon T, Van Pel A (1989) T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by transcription and translation of short subgenic regions. A hypothesis. Immunogenetics 29:75-79.
10. Schwab SR, Shugart JA, Horng T, Malarkannan S, Shastri N (2004) Unanticipated antigens: Translation initiation at CUG with leucine. PLoS Biol 2:e366.
11. Reits E, et al. (2003) Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 18:97-108.
12. Falk K, Rötzschke O, Rammensee HG (1990) Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 348:248-251.
13. Istrail S, et al. (2004) Comparative immunopeptidomics of humans and their pathogens. Proc Natl Acad Sci USA 101:13268-13272.
14. Demaria S, Bushkin Y (2000) Soluble HLA proteins with bound peptides are released from the cell surface by the membrane metalloproteinase. Hum Immunol 61: 1332-1338.
15. Krangel MS (1986) Secretion of HLA-A and -B antigens via an alternative RNA splicing pathway. J Exp Med 163:1173-1190.
16. van Rood JJ, van Leeuwen A, van Santen MC (1970) Anti HL-A2 inhibitor in normal human serum. Nature 226:366-367.
17. Campoli M, Ferrone S (2008) Tumor escape mechanisms: Potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 72:321-334.
18. Zavazava N, Krönke M (1996) Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med 2:1005-1010.
19. Hickman HD, et al. (2000) C-terminal epitope tagging facilitates comparative ligand mapping from MHC class I positive cells. Hum Immunol 61:1339-1346.
20. Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56:227-236.